Prelude Therapeutics Stock Fundamentals
| PRLD Stock | USD 0.95 0.02 2.20% |
Prelude Therapeutics fundamentals help investors to digest information that contributes to Prelude Therapeutics' financial success or failures. It also enables traders to predict the movement of Prelude Stock. The fundamental analysis module provides a way to measure Prelude Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Prelude Therapeutics stock.
At present, Prelude Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 1.6 M, whereas Selling General Administrative is forecasted to decline to about 18.9 M. Prelude | Select Account or Indicator |
Prelude Therapeutics Company Return On Equity Analysis
Prelude Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Prelude Therapeutics Return On Equity | -0.67 |
Most of Prelude Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prelude Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Prelude Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Prelude Therapeutics has a Return On Equity of -0.6664. This is 97.22% lower than that of the Biotechnology sector and 98.17% lower than that of the Health Care industry. The return on equity for all United States stocks is 114.97% higher than that of the company.
Prelude Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Prelude Therapeutics's current stock value. Our valuation model uses many indicators to compare Prelude Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prelude Therapeutics competition to find correlations between indicators driving Prelude Therapeutics's intrinsic value. More Info.Prelude Therapeutics is regarded second in return on equity category among its peers. It is regarded third in return on asset category among its peers . At present, Prelude Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Prelude Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Prelude Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prelude Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics of similar companies.Prelude Therapeutics is currently under evaluation in return on equity category among its peers.
Prelude Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Prelude Therapeutics from analyzing Prelude Therapeutics' financial statements. These drivers represent accounts that assess Prelude Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Prelude Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 848.9M | 3.1B | 592.6M | 286.1M | 257.7M | 244.8M | |
| Enterprise Value | 830.3M | 2.9B | 562.6M | 257.4M | 249.3M | 236.9M |
Prelude Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (11.46) % | ||||
| Current Valuation | (82.26 M) | ||||
| Shares Outstanding | 42.18 M | ||||
| Shares Owned By Insiders | 9.06 % | ||||
| Shares Owned By Institutions | 85.00 % | ||||
| Number Of Shares Shorted | 2.94 M | ||||
| Price To Book | 0.34 X | ||||
| Price To Sales | 17.74 X | ||||
| EBITDA | (131.11 M) | ||||
| Net Income | (121.83 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 16.89 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 2.84 X | ||||
| Cash Flow From Operations | (107.06 M) | ||||
| Short Ratio | 9.84 X | ||||
| Earnings Per Share | (1.77) X | ||||
| Price To Earnings To Growth | (0.09) X | ||||
| Target Price | 5.4 | ||||
| Number Of Employees | 128 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 53.23 M | ||||
| Total Asset | 277.67 M | ||||
| Retained Earnings | (456.39 M) | ||||
| Working Capital | 213.76 M | ||||
| Net Asset | 277.67 M |
About Prelude Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prelude Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prelude Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prelude Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 13.3 M | 11.9 M | |
| Cost Of Revenue | 1.2 M | 1.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out Prelude Therapeutics Piotroski F Score and Prelude Therapeutics Altman Z Score analysis. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share 0.04 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.